معرفی
Dr. Paul E. Love is a Senior Investigator and tenured Principal Investigator at the National Institutes of Health (NIH), specifically within the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), where he leads the Section on Hematopoiesis and Lymphocyte Biology. His research is focused on the molecular and cellular mechanisms regulating mammalian hematopoiesis, with an emphasis on T cell development, T cell receptor (TCR) signaling, thymocyte selection, and the pathogenesis of hematopoietic malignancies such as T-cell acute lymphoblastic leukemia (T-ALL).
Dr. Love earned his B.S. in Biochemistry from Syracuse University, followed by an M.D. and Ph.D. through the Medical Scientist Training Program at the University of Rochester. He completed clinical training in Laboratory Medicine at Washington University, St. Louis, and a fellowship in Human Genetics at NICHD before joining the NIH intramural program, where he became a Principal Investigator in 1993. His lab utilizes genetically engineered mouse models, transgenic technology, and advanced genomic techniques including RNA-seq and ChIP-seq to dissect the roles of key signaling molecules such as TCR subunits, CD5, Themis family proteins, Fbxl12, and the nuclear adapter protein Ldb1.
His research has revealed fundamental insights into TCR signaling, including the discovery that CD3ζ ITAMs have dual activating and inhibitory roles depending on antigen affinity—a finding with major implications for cancer immunotherapy. His work on Themis demonstrated its role in enhancing TCR signaling by inhibiting the phosphatase SHP-1, thereby promoting thymocyte positive selection. Additionally, his lab has shown that Ldb1 is essential for hematopoietic stem cell maintenance and plays a critical role in Lmo2-induced leukemogenesis, identifying Ldb1 complexes as potential therapeutic targets in pediatric T-ALL.
The most recent publications highlight ongoing work in TCR tuning, thymocyte development, and transcriptional regulation in hematopoiesis. Key themes across his article output include signal transduction in immune cells, molecular mechanisms of thymocyte selection, regulation of self-renewal in hematopoietic and leukemic cells, and translational applications in immunotherapy and leukemia. His work bridges basic immunology and clinical relevance, with implications for autoimmune diseases and cancer treatment.
Dr. Love has received several honors, including:
- NIH Bench to Bedside Award (2023–2024)
- NICHD Director's Award (2023–2024)
He mentors a team of scientists and trainees, including staff scientists, research and visiting fellows, and technicians. His lab collaborates extensively with researchers across the NIH and international institutions. Dr. Love’s long-standing contributions to immunology and hematopoiesis continue to shape understanding of immune cell development and offer new avenues for therapeutic intervention.
His laboratory investigates key questions in hematopoietic stem cell biology, T and B cell development, signal transduction, and transcriptional regulation. The lab uses a multidisciplinary approach combining mouse genetics, molecular biology, and systems immunology to study how signaling pathways and transcriptional networks govern cell fate decisions in the immune system. Current projects include exploring the therapeutic potential of modulating TCR signaling for cancer immunotherapy and dissecting the role of Ldb1 complexes in leukemogenesis.
